Basic Considerations

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

Fayad ZA, for the dal-PLAQUE Investigators (Translational and Molecular Imaging Inst, NY; et al) Lancet 378:1547–1559, 2011^§

Abstract

Background

Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE is the first multicentre study using novel non-invasive multimodality imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints.

Methods

In this phase 2b, double-blind, multicentre trial, patients (aged 18–75 years) with, or with high risk of, coronary heart disease were randomly assigned (1:1) to dalcetrapib 600 mg/day or placebo for 24 months. Randomisation was done with a computer-generated randomisation code and was stratified by centre. Patients and investigators were masked to treatment. Coprimary endpoints were MRI-assessed indices (total vessel area, wall area, wall thickness, and normalised wall index [average carotid]) after 24 months and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET/CT assessment of arterial inflammation within an index vessel (right carotid, left carotid, or ascending thoracic aorta) after 6 months, with no-harm boundaries established before unblinding of the trial. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00655473.

Findings

189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients). For the coprimary MRI and PET/CT endpoints, CIs were below the no-harm boundary or the adverse change was numerically lower in the dalcetrapib group than in the placebo group. MRI-derived change in total vessel area was reduced in patients given dalcetrapib compared with those given placebo after 24 months; absolute change from baseline relative to placebo was −4·01 mm² (90% CI −7·23 to −0·80; nominal p = 0·04). The PET/CT measure of index vessel most-diseased-segment target-to-background ratio (TBR) was not different between groups, but carotid artery analysis showed a 7% reduction in most-diseased-segment TBR in the dalcetrapib group compared with the placebo group (−7·3 [90% CI −13·5 to −0·8]; nominal p = 0·07). Dalcetrapib did not increase office blood pressure and the frequency of adverse events was similar between groups.

Interpretation

Dalcetrapib showed no evidence of a pathological effect related to the arterial wall over 24 months. Moreover, this trial suggests possible beneficial vascular effects of dalcetrapib, including the reduction in total vessel enlargement over 24 months, but long-term safety and clinical outcomes efficacy of dalcetrapib need to be analysed (Figs 2–4).

Figure 2 Mean carotid total vessel area and percent increase in average carotid total vessel area (by MRI). (A) Raw mean data (90% CI) for total vessel area at baseline, 6, 12, and 24 months. Total vessel area increased after 24 months in the placebo group: model-derived, corrected average absolute change (24 months–baseline) was 5·72 mm² (90% CI 3·30–8·14), p=0·0002. However, in the dalcetrapib group, total vessel area did not change in the same period (1·71 [−0·68 to 4·10], p=0·24). The average reduction in total vessel area on dalcetrapib (versus placebo), after correction of baseline, was −4·01 (−7·23 to −0·80), p=0·04. (B) Group mean data for percent change in total vessel area at 6, 12, and 24 months (relative to baseline). In patients assigned placebo, model-derived, corrected total vessel area increased in the initial 24 months: percent change total vessel area was 10·8 (90% CI 5·8–15·8), p=0·001. However, in patients assigned dalcetrapib, total vessel area did not increase in the same period (4·0% [0·6–7·3], p=0·16). The average percent change in total vessel area in the dalcetrapib group (versus placebo), after correction of baseline, was −7·1% (−12·8 to −1·3), p=0·04. (Reprinted from The Lancet, Fayad ZA, for the dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547–1559. Copyright 2011, with permission from Elsevier.)

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Function Testing of Platelets and Long-term Outcome of Patients with Peripheral Arterial Disease Undergoing Transluminal Angioplasty
2. of Hypoxia-Inducible Factor-1α Gene Therapy on Walking Performance in Patients With Intermittent Claudication
3. Proximal Endografting With Distal Bare-Metal Stenting for Management of Aortic Dissection
4. and Removal of Inferior Vena Cava Filters: National Trends in the Medicare Population

Stay updated, free articles. Join our Telegram channel

Join